Lisanne de Koster, ETA 2021: FDG-PET/CT Prior to Diagnostic Thyroid Surgery
We caught up with Dr Lisanne de Koster, (Radboud University Medical Center, Nijmegen, The Netherlands) to discuss her study which investigated whether the use of FDG-PET/CT could prevent unnecessary diagnostic thyroid surgery.
The abstract ‘Efficacy of 18F-FDG-PET/CT in evaluation of cytological indeterminate thyroid nodules prior to surgery (EfFECTS): a randomised-controlled multicentre trial’ (Abstract 49) was presented at the European Thyroid Association (ETA) Annual Meeting 2021, 4-7 September 2021.
1. How is papillary thyroid cancer currently diagnosed and prognosed? (0:15)
2. Why is it important to avoid unbeneficial diagnostic thyroid lobectomies and how might fludeoxyglucose (18F-FDG)-PET/CT imaging improve preoperative differentiation? (0:53)
3. What impact did FDG-PET/CT imaging have on unbeneficial diagnostic thyroid lobectomies? (2:36)
4. Are there any nodule types where FDG-PET/CT imaging was more or less useful in pre-operative nodule differentiation? (03:14)
5. What impact will these findings have on patients and is there anything more that needs to be done to inform clinical management guidelines (04:13)
Disclosures: Dr Lisanne de Koster has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Louise Taylor.
Filmed in coverage of the European Thyroid Association (ETA) Annual Meeting 2021, 4-7 September 2021.
18F-FDG = 2-deoxy-2-[fluorine-18]fluoro-D-glucose; CT = computed tomography; PT = positron emission.
de Koster EJ, De Geus-Oei L-F, Brouwers AH, et al. 49: Efficacy of 18F-FDG-PET/CT in evaluation of cytological indeterminate thyroid nodules prior to surgery (EfFECTS): a randomised-controlled multicentre trial. Eur Thyroid J 2021;10(Suppl. 1):13.
Share this Video
Related Videos In Thyroid Disorders
Julie Ann Sosa, MD, MA, FACS: American Thyroid Association (ATA) centennial celebration
We caught up with the American Thyroid Association (ATA) president Prof. Julie Ann Sosa, MD, MA, FACS (University of California, San Francisco, CA, USA) ahead of this year’s virtual meeting to highlight their ATA Centennial Celebration at their upcoming conference taking place in Washington, DC in 2023. The 2023 American Thyroid Association Annual Meetings Centennial […]
Glenn Braunstein: Research highlights from 2022 in thyroid disorders
There has also been high interest in the treatment of hypothyroidism in older adults, the treatment of thyroid eye disease and the increase of radiofrequency ablation for thyroid nodules to reduce their size by 50% to 97%. We were delighted to speak with our editorial board member Prof. Glenn Braunstein (Cedars-Sinai Medical Center, Los Angeles, […]
Kristien Boelaert, ATA 2022: The EGRET study: Long term mortality and cardiometabolic effects of hyperthyroidism treatment
Current evidence indicates cardio‐metabolic effects from antithyroid drugs and other definitive treatment options for hyperthyroidism. The EGRET study aimed to assess the differences in mortality and cardiometabolic outcomes depending on the method of treatment in order to better inform patient‐clinician decision‐making. In this touchENDOCRINOLOGY interview, Prof. Kristien Boelaert (University of Birmingham, Birmingham, United Kingdom) discusses […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!